In a market where clinical timelines and capital discipline increasingly shape sentiment, Bolt Biotherapeutics Inc. (BOLT) has emerged as a name drawing renewed attention.
The stock posted a modest gain of 3.33% in after-hours trading, rising to $6.05 following a 2.36% uptick during the regular session. While the move may appear incremental, it comes amid a series of strategic and clinical updates that signal a recalibration of the company's near-term trajectory.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com